NovaBay Pharmaceuticals Inc (NBY)

4.70
0.07 1.62
AMEX : Health Care
Prev Close 4.62
Open 4.60
Day Low/High 4.30 / 4.70
52 Wk Low/High 1.62 / 16.23
Volume 29.70K
Avg Volume 21.00K
Exchange AMEX
Shares Outstanding 15.31M
Market Cap 69.66M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

NovaBay Pharmaceuticals Announces CFO Transition

NovaBay Pharmaceuticals Announces CFO Transition

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a specialty pharmaceutical company focusing on commercializing prescription Avenova ® for lid and lash hygiene in the domestic eye care market, announces that...

NovaBay Pharmaceuticals Joins The Russell Microcap Index

NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® lid and lash hygiene for the domestic eye care market, announces that it has...

NovaBay Pharmaceuticals To Present At The 7th Annual LD Micro Invitational

NovaBay ® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® lid and lash hygiene for the domestic eye care market, announces that management is...

NovaBay Pharmaceuticals Receives Noncompliance Notice From NYSE MKT

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) today announced receipt of a letter from NYSE MKT LLC ("NYSE MKT" or the "Exchange") on May 16, 2017, stating that it is not in compliance with the continued listing...

NovaBay Pharmaceuticals Reports First Quarter 2017 Financial Results

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a pharmaceutical company focused on commercializing its prescription Avenova ® lid and lash hygiene product for the domestic eye care market, reports financial...

NovaBay Pharmaceuticals To Hold 2017 First Quarter Conference Call On May 11, 2017

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova ® lid and lash hygiene product for the domestic eye care market, announces that it...

NovaBay Pharmaceuticals Reports 2016 Full Year And Fourth Quarter Financial Results And Provides 2017 Financial Guidance

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a pharmaceutical company focusing on commercializing its prescription Avenova ® lid and lash hygiene product for the domestic eye care market, reports financial...

NovaBay Pharmaceuticals To Hold 2016 Fourth Quarter And Full Year Conference Call On March 23, 2017

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova ® lid and lash hygiene product for the domestic eye care market, announces that it...

NovaBay Pharmaceuticals To Present Features And Benefits Of The Intelli-Case At FDA Public Advisory Meeting

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a pharmaceutical company focusing on commercializing its Avenova® lid and lash hygiene in the domestic eye care market, today announced that it has been...

NovaBay Pharmaceuticals To Present At 29th Annual ROTH Conference

NovaBay ® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® lid and lash hygiene for the domestic eye care market, announces that Chairman,...

NovaBay Pharmaceuticals Announces Preliminary Sales For The Fourth Quarter Of 2016

NovaBay Pharmaceuticals Announces Preliminary Sales For The Fourth Quarter Of 2016

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® lid and lash hygiene for the domestic eye care market, announces that Avenova...

NovaBay To Present At LD Micro Main Event

NovaBay To Present At LD Micro Main Event

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its Avenova® lid and lash hygiene product for the domestic eye care market, announces that Chairman,...

NovaBay Pharmaceuticals Reports 2016 Third Quarter Financial Results

NovaBay Pharmaceuticals Reports 2016 Third Quarter Financial Results

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova ® lid and lash hygiene product for the domestic eye care market, reports financial...

NovaBay Pharmaceuticals To Hold Third Quarter 2016 Conference Call On November 10

NovaBay Pharmaceuticals To Hold Third Quarter 2016 Conference Call On November 10

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova ® lid and lash hygiene product for the domestic eye care market, announces...

NovaBay Pharmaceuticals Successfully Regains Compliance With NYSE Continued Listing Requirements

NovaBay Pharmaceuticals Successfully Regains Compliance With NYSE Continued Listing Requirements

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® lid and lash hygiene for the domestic eye care market, announces that it has...

NovaBay Pharmaceuticals Receives $7 Million From Early Warrant Exercise

NovaBay Pharmaceuticals Receives $7 Million From Early Warrant Exercise

NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® lid and lash hygiene for the domestic eye care market, announces that during the...

NovaBay Pharmaceuticals' Auriclosene® Demonstrates Statistically Significant And Clinically Meaningful Results In Phase 2b Study For The Prevention Of Urinary Catheter Blockage And Encrustation

NovaBay Pharmaceuticals' Auriclosene® Demonstrates Statistically Significant And Clinically Meaningful Results In Phase 2b Study For The Prevention Of Urinary Catheter Blockage And Encrustation

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company, announces that data from a Phase 2b clinical study with Auriclosene Irrigating Solution (AIS) demonstrated statistically significant and...

NovaBay Pharmaceuticals' Neutrox® Product Line Receives CE Mark And ISO Certification For The European Union

NovaBay Pharmaceuticals' Neutrox® Product Line Receives CE Mark And ISO Certification For The European Union

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® lid and lash hygiene in the domestic eye care market, announces that its...

NovaBay Pharmaceuticals To Present At The Rodman & Renshaw Global Investment Conference

NovaBay Pharmaceuticals To Present At The Rodman & Renshaw Global Investment Conference

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its Avenova ® lid and lash hygiene for the domestic eye care market, announces that President and CEO Mark...

NovaBay Pharmaceuticals Reports 2016 Second Quarter Financial Results

NovaBay Pharmaceuticals Reports 2016 Second Quarter Financial Results

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova lid and lash hygiene product for the domestic eye care market, reports financial...

NovaBay Pharmaceuticals To Hold Second Quarter 2016 Conference Call On August 11

NovaBay Pharmaceuticals To Hold Second Quarter 2016 Conference Call On August 11

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova ® lid and lash hygiene product for the domestic eye care market, announces that it...

NovaBay Pharmaceuticals Completes $11.8 Million Private Placement

NovaBay Pharmaceuticals Completes $11.8 Million Private Placement

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® lid and lash hygiene for the domestic eye care market, announces the closing of...

NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek President And Chief Executive Officer

NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek President And Chief Executive Officer

NovaBay ® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® lid and lash hygiene for the domestic eye care market, announces the appointment of...

NovaBay Pharmaceuticals Reports 2016 First Quarter Financial Results

NovaBay Pharmaceuticals Reports 2016 First Quarter Financial Results

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova lid and lash hygiene product for the domestic eye care market, reports financial...

NovaBay Pharmaceuticals Appoints Todd Zavodnick To Its Board Of Directors

NovaBay Pharmaceuticals Appoints Todd Zavodnick To Its Board Of Directors

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its Avenova ® lid and lash hygiene product for the domestic eye care market, announces the appointment of...

NovaBay Pharmaceuticals To Hold First Quarter 2016 Conference Call On May 12

NovaBay Pharmaceuticals To Hold First Quarter 2016 Conference Call On May 12

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova ® lid and lash hygiene product for the domestic eye care market, announces...

Clinical Data Presented At ARVO Showing NovaBay's Avenova Reduces Bacteria On Ocular Skin Surface By More Than 90%

Clinical Data Presented At ARVO Showing NovaBay's Avenova Reduces Bacteria On Ocular Skin Surface By More Than 90%

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) a biopharmaceutical company focusing on commercializing its Avenova ® Lid and Lash Hygiene product for the domestic eye care market, announces the presentation...

NovaBay Pharmaceuticals Announces Agreement For Nearly $12 Million In Two-Tranche Private Placement

NovaBay Pharmaceuticals Announces Agreement For Nearly $12 Million In Two-Tranche Private Placement

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) a biopharmaceutical company focusing on commercializing its Avenova ® Lid and Lash Cleanser for the domestic eye care market, announces that it has entered...